Anti-chemokine antibodies after SARS-CoV-2 infection correlate with favorable disease course
J. Muri, V. Cecchinato, A. Cavalli, A. A. Shanbhag, M. Matkovic, M. Biggiogero, P. A. Maida, J. Moritz, C. Toscano, E. Ghovehoud, R. Furlan, F. Barbic, A. Voza, G. De Nadai, C. Cervia, , Franzetti-Pelland
The paper finds that anti-chemokine antibodies after SARS-CoV-2 infection correlate with favorable disease outcomes and predict absence of long COVID symptoms.
bioRxiv · May 23, 2022 · PreprintImmunology